Table 2. The prognostic value of PRDX1 mRNA expression in ovarian cancer.

	Overall survival			Progress-free survival
	Cases	HR (95% CI)	P-value	Cases	HR (95% CI)	P-value
Histology
All cancer patients	1656	1.09 (0.96–1.25)	0.19	1435	1.07 (0.94–1.21)	0.31
Serous cancer patients	1207	1.15 (0.98–1.36)	0.092	1104	0.91 (0.78–1.06)	0.24
Endometrioid cancer patients	37	2.1 (0.35–12.6)	0.41	51	0.3 (0.07–1.29)	0.086
Pathological grades
I	56	0.25 (0.09–0.7)	0.0044*	37	0.14 (0.04–0.42)	5.4e−05*
II	324	0.71 (0.52–0.97)	0.028*	256	0.75 (0.53–1.05)	0.094
III	1015	0.92 (0.75–1.12)	0.4	837	0.91 (0.77–1.09)	0.3
Clinical stages
I and II	135	0.52 (0.18–1.5)	0.22	163	2.12 (1.06–4.27)	0.03*
III and IV	1220	1.15 (0.98–1.35)	0.084	1081	0.89 (0.76–1.04)	0.15
Chemotherapy
Contains Platin	1409	0.91 (0.77–1.07)	0.26	1259	1.08 (0.95–1.23)	0.24
Contains Taxol	793	1.17 (0.96–1.41)	0.12	715	0.9 (0.76–1.07)	0.23
Contains Taxol+Platin	776	1.16 (0.95–1.41)	0.14	698	0.9 (0.75–1.07)	0.24

*P<0.05.